로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IL23A & IL12B

IL23A & IL12B

요약

Name:Interleukin-23
Target Synonym:Interleukin-23
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

ILB-H5219-Cell-based assay
 IL23A & IL12B CELL

Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) stimulates proliferation of Human IL-23 R/IL-12 R beta 1(Luc) HEK293 Reporter Cell. The specific activity of Human IL-23A&IL-12B Heterodimer Protein, premium grade is > 1.80 X 10^3 U/mg (QC tested).

ILB-H82W6-Cell-based assay
 IL23A & IL12B CELL

Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) stimulates secretion of IL-17 by mousespleen cells. The ED50 for this effect is 0.191-0.2173 ng/mL (Routinely tested).

ILB-H82W6-SPR
 IL23A & IL12B SPR

Captured Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (Cat. No. ILR-H52H4) affinity constant of 4.77 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

ILB-H52W5-SPR
 IL23A & IL12B SPR

Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL23A & IL12B Molecule Synonym Name

IL-23 alpha & IL-12 beta

IL23A & IL12B Molecule Background

Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.

IL23A & IL12B References

Related Molecule

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ustekinumab C-340; CNTO-1275 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary Details
Ustekinumab biosimilar(Formycon) FYB-202 Approved Formycon AG OTULFI EU Crohn Disease; Colitis, Ulcerative Fresenius Kabi Deutschland Gmbh, Formycon AG 2024-09-25 Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab Biosimilar (qyuns) QX-001S; QX-001-S; HDM-3001 Approved Qyuns Therapeutics Co Ltd Mainland China Plaque psoriasis Qyuns Therapeutics Co Ltd 2024-10-29 Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Approved Celltrion Inc Steqeyma, Steqeyma IV Canada Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease Celltrion Inc 2024-08-01 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar (Biocon) Approved Biocon Biologics Ltd Bmab 1200, Yesintek United States Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease Biocon Biologics Inc 2024-11-29 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) Japan Arthritis, Psoriatic; Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA, wezenla United States Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab biosimilar(DM Bio) DA-3115; DMB-3115 Approved Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd IMULDOSA, Absimky United States Psoriasis Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd 2024-10-11 Psoriasis; Colitis, Ulcerative; Crohn Disease Details
Ustekinumab C-340; CNTO-1275 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary Details
Ustekinumab biosimilar(Formycon) FYB-202 Approved Formycon AG OTULFI EU Crohn Disease; Colitis, Ulcerative Fresenius Kabi Deutschland Gmbh, Formycon AG 2024-09-25 Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab Biosimilar (qyuns) QX-001S; QX-001-S; HDM-3001 Approved Qyuns Therapeutics Co Ltd Mainland China Plaque psoriasis Qyuns Therapeutics Co Ltd 2024-10-29 Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Approved Celltrion Inc Steqeyma, Steqeyma IV Canada Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease Celltrion Inc 2024-08-01 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar (Biocon) Approved Biocon Biologics Ltd Bmab 1200, Yesintek United States Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease Biocon Biologics Inc 2024-11-29 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) Japan Arthritis, Psoriatic; Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA, wezenla United States Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab biosimilar(DM Bio) DA-3115; DMB-3115 Approved Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd IMULDOSA, Absimky United States Psoriasis Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd 2024-10-11 Psoriasis; Colitis, Ulcerative; Crohn Disease Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
mRNA-2752 mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
SFA-002 SFA-002; SFA002 Phase 1 Clinical Arthritis, Rheumatoid; Plaque psoriasis Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab biosimilar (Curateq Biologics) BP38; BP-38 Phase 1 Clinical CuraTeQ Biologics Pvt Ltd Psoriasis Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details
Ustekinumab biosimilar (BioFactura) BFI-751 BioFactura Australia Pty Ltd Details
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
mRNA-2752 mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
SFA-002 SFA-002; SFA002 Phase 1 Clinical Arthritis, Rheumatoid; Plaque psoriasis Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab biosimilar (Curateq Biologics) BP38; BP-38 Phase 1 Clinical CuraTeQ Biologics Pvt Ltd Psoriasis Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details
Ustekinumab biosimilar (BioFactura) BFI-751 BioFactura Australia Pty Ltd Details

This web search service is supported by Google Inc.

totop